Skip to main content

Table 2 Demographic data

From: Faster recovery and reduced paracetamol use – a meta-analysis of EPs 7630 in children with acute respiratory tract infections

Indication Study, reference Treatment Age (years) mean ± SD, range Sex
Female Male
Acute tonsillopharyngitis A Timen et al., 2015 [60] EPs 7630 (n = 40) 7.4 ± 1.2, 6–9 26 (65.0%) 14 (35.0%)
Placebo (n = 38) 7.7 ± 1.2, 6–9 18 (47.4%) 20 (52.6%)
B Berezhnoi et al., 2016 [55] EPs 7630 (n = 60) 7.6 ± 1.1, 6–9 29 (48.3%) 31 (51.7%)
Placebo (n = 64) 7.4 ± 1.2, 6–9 28 (43.8%) 36 (56.3%)
C Bereznoy et al., 2003 [56] EPs 7630 (n = 73) 7.6 ± 1.3, 6–9 40 (54.8%) 33 (45.2%)
Placebo (n = 70) 7.5 ± 1.1, 6–9 30 (42.9%) 40 (57.1%)
Acute bronchitis D§ Kamin et al., 2010a [58] EPs 7630 (n = 25) 7.8 ± 1.3, 6–10 14 (56.0%) 11 (44.0%)
Placebo (n = 24) 7.9 ± 1.7, 6–10 11 (45.8%) 13 (54.2%)
E§ Kamin et al., 2010b [59] EPs 7630 (n = 32) 8.2 ± 1.3, 6–10 16 (50.0%) 16 (50.0%)
Placebo (n = 31) 7.9 ± 1.5, 6–10 15 (48.4%) 16 (51.6%)
F§ Kamin et al., 2012 [57] EPs 7630& (n = 35) 7.7 ± 1.3, 6–10 21 (60.0%) 14 (40.0%)
Placebo (n = 31) 7.4 ± 1.3, 6–10 16 (51.6%) 15 (48.4%)
Pooled data (acute tonsillopharyngitis + acute bronchitis) EPs 7630 (n = 265) 7.7 ± 1.2, 6–10 146 (55.1%) 119 (44.9%)
Placebo (n = 258) 7.6 ± 1.3, 6–10 118 (45.7%) 140 (54.3%)
  1. § Only children 6–10 years of age
  2. & Only children randomised to 3 × 20 mg/day